What the Science Shows
MOTS-c prevented diet-induced obesity in animal studies, but there is no published evidence from human clinical trials demonstrating weight loss effects in people. The peptide shows promise in preclinical research, but significant gaps remain between laboratory findings and proven therapeutic applications. [1-2]
Animal Study Findings
Research in mice demonstrates that MOTS-c treatment prevented both age-dependent and high-fat-diet-induced obesity. [1]
In the landmark 2015 study published in Cell Metabolism, mice receiving MOTS-c while on a high-fat diet did not develop the obesity seen in untreated animals. [1]
Additional animal studies support these findings:
- Postmenopausal obesity model: MOTS-c prevented ovariectomy-induced weight gain in mice by increasing brown fat activation and reducing white fat accumulation. [3]
- Aging models: Treatment reduced abnormal lipid accumulation in liver, visceral fat, and skin in mice treated with D-galactose (an aging model). [4]
- Fat tissue effects: MOTS-c reduced fat mass, suppressed inflammatory responses in adipose tissue, and lowered fatty acid levels in serum and liver. [3]
How MOTS-c Works
MOTS-c targets skeletal muscle and activates AMPK (AMP-activated protein kinase), often called the cell’s “master energy sensor.” The peptide inhibits the folate cycle and purine biosynthesis, leading to AMPK activation, which then: [1]
- Enhances glucose uptake into muscle cells
- Improves insulin sensitivity
- Increases energy expenditure
- Promotes mitochondrial function
- Activates brown fat (which burns calories) [3][5]
During metabolic stress, MOTS-c can also move into the cell nucleus to regulate genes involved in stress adaptation and metabolism. [5-6]
The Human Evidence Gap
No clinical trials have tested whether MOTS-c causes weight loss in humans. The existing human research consists only of observational studies measuring natural MOTS-c levels in people’s blood, not interventional studies administering the peptide. [2]
What we know from human observational studies:
- Obese male children and adolescents have lower circulating MOTS-c levels compared to lean controls. [7]
- In one small study of adults, plasma MOTS-c levels were similar between lean and obese individuals, though the relationship with insulin resistance differed between groups. [8]
- Exercise increases MOTS-c levels in some populations, and higher post-exercise MOTS-c correlated with reductions in fat mass and body weight—but this was from exercise, not MOTS-c administration. [9]
Important Limitations
Several critical factors limit the translation of animal findings to human weight loss:
No approved clinical use: Reviews consistently note that “no effective method of applying MOTS-c in the clinic has been developed.” There are no established formulations, dosing protocols, or delivery methods for human use. [2]
Bioavailability challenges: The peptide faces “low bioavailability, poor stability and high synthesis costs,” which present barriers to clinical development. [10]
Species differences: All obesity studies used rodent models. Differences in metabolism, body composition, and drug responses between mice and humans may affect whether results translate.
Prevention vs. treatment: Most animal studies tested whether MOTS-c prevents obesity when given alongside a high-fat diet, not whether it causes weight loss in already-obese animals.
Safety unknown: No published human safety data exists. Comprehensive toxicology studies, dose-ranging trials, and long-term safety monitoring in humans have not been conducted or published.
What This Means
While MOTS-c shows metabolic benefits in laboratory animals, calling it a weight loss treatment for humans is premature and unsupported by clinical evidence. The peptide remains a research tool for understanding metabolism, not a proven therapy.
Before MOTS-c could be considered for weight management in humans, researchers would need to:
- Develop stable pharmaceutical formulations
- Conduct phase I safety and pharmacokinetic studies
- Perform randomized controlled trials testing efficacy for weight loss
- Establish optimal dosing, duration, and patient selection criteria
- Demonstrate long-term safety and sustained benefits
The gap between promising preclinical data and human clinical application represents years of research and development that has not yet occurred.
References
- The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance.
Lee C, Zeng J, Drew BG, et al. Cell Metabolism. 2015;21(3):443-54. doi:10.1016/j.cmet.2015.02.009. - MOTS-c: A Promising Mitochondrial-Derived Peptide for Therapeutic Exploitation. Zheng Y, Wei Z, Wang T. Frontiers in Endocrinology. 2023;14:1120533. doi:10.3389/fendo.2023.1120533.
- MOTS-c Peptide Regulates Adipose Homeostasis to Prevent Ovariectomy-Induced Metabolic Dysfunction.
Lu H, Wei M, Zhai Y, et al. Journal of Molecular Medicine (Berlin, Germany). 2019;97(4):473-485. doi:10.1007/s00109-018-01738-w. - Earlier Changes in Mice After D-Galactose Treatment Were Improved by Mitochondria Derived Small Peptide MOTS-c.
Li Q, Lu H, Hu G, et al. Biochemical and Biophysical Research Communications. 2019;513(2):439-445. doi:10.1016/j.bbrc.2019.03.194. - Mitochondria-Derived Peptide MOTS-c: Effects and Mechanisms Related to Stress, Metabolism and Aging.
Wan W, Zhang L, Lin Y, et al. Journal of Translational Medicine. 2023;21(1):36. doi:10.1186/s12967-023-03885-2. - The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.
Kim KH, Son JM, Benayoun BA, Lee C. Cell Metabolism. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008. - Circulating MOTS-c Levels Are Decreased in Obese Male Children and Adolescents and Associated With Insulin Resistance.
Du C, Zhang C, Wu W, et al. Pediatric Diabetes. 2018;. doi:10.1111/pedi.12685. - Plasma MOTS-c Levels Are Associated With Insulin Sensitivity in Lean but Not in Obese Individuals.
Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Journal of Investigative Medicine : The Official Publication of the American Federation for Clinical Research. 2018;66(6):1019-1022. doi:10.1136/jim-2017-000681. - Effect of Aerobic and Resistance Exercise on the Mitochondrial Peptide MOTS-c in Hispanic and Non-Hispanic White Breast Cancer Survivors.
Dieli-Conwright CM, Sami N, Norris MK, et al. Scientific Reports. 2021;11(1):16916. doi:10.1038/s41598-021-96419-z. - Mitochondria‑derived Peptides: Promising Microproteins in Cardiovascular Diseases (Review).
Ran Y, Guo Z, Zhang L, et al. Molecular Medicine Reports. 2025;31(5):127. doi:10.3892/mmr.2025.13492.
